Completed PHASE4 INTERVENTIONAL 2-arm NCT03701061

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Sponsor: Emory University

Conditions Influenza A Subtype H5N1 Infection

Interventions Seasonal Influenza Vaccine

Updated 9 times since 2018 Last updated: Feb 28, 2020 Started: Oct 11, 2018 Primary completion: Feb 28, 2019 Completion: Jan 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Influenza A Subtype H5N1 Infection and is currently completed. Emory University leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Apr 2020 — Jan 2021 [monthly]

Completed PHASE4
Mar 2020 — Apr 2020 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Sep 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Nov 2018 — Sep 2019 [monthly]

Recruiting PHASE4

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Decatur, United States